Physician profile
Abi Watts
NPI 1689229445
$2,087.96
in general payments reported to CMS, 2019-2025
14 companies · $992 in 2025
The $992 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $108 · 2024: $987 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Grant: $333 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.63 |
| Grant | $333.34 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $571.02 | 2024-2025 | Avvigo Guidance System |
| Abiomed | $304.80 | 2025 | |
| Medtronic, INC. | $250.94 | 2023-2024 | Onyx Frontier, Telescope, Hawkone |
| Actelion Pharmaceuticals US, INC. | $224.77 | 2025 | Opsumit, Uptravi |
| Pfizer INC. | $203.12 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $147.08 | 2025 | Wainua, Bevespi Aerosphere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.12 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $79.50 | 2025 | Verquvo |
| Biotronik INC. | $70.00 | 2023 | Passeo-18, Pulsar-18 T3 |
| Abbott Laboratories | $49.77 | 2025 | Cardiomems, Durata |
| Alnylam Pharmaceuticals INC. | $33.94 | 2025 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $28.61 | 2024 | |
| Biosense Webster, INC. | $27.37 | 2024 | Carto 3 |
| Cvrx, INC. | $12.92 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abi Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.